Gain Therapeutics GANX 深 沪
等待开盘 12-27 09:30:00 美东时间
3.15
-0.070
-2.17%
华盛通- 最 高3.21
- 今 开3.20
- 成交量 57.63万股
- 最 低 3.05
- 昨 收 3.22
- 总市值 1.21亿
- 52周最高 4.34
- 市盈率 静 --
- 换手率 1.50%
- 52周最低 1.41
- 委 比 69.83%
- 总股本 3846.21万
- 历史最高 17.93
- 量 比 0.12
- 振 幅 4.97%
- 历史最低 0.89
- 每 手 1
- 风险率 0.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
12-22 15:05
美股牛股 | 太空概念股普涨，LUNR涨近38%；爱美医疗涨超30%，获拜玛林制药48亿美元收购
NovaBay Pharmaceuticals涨79.7%；Lunar Corporation涨37.7%；D-MARKET Electronic Services & Trading涨37.1%
12-20 10:49
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Athira Pharma (NASDAQ:ATHA) stock rose 70.0% to $7.03 during Thursday'...
12-19 01:06
Gain Therapeutics Reports Encouraging Phase 1b Parkinson’s Data
An update from Gain Therapeutics ( ($GANX) ) is now available. On December 18, ...
12-18 22:27
Gain Therapeutics Reports Early Parkinson's Study Showing Brain Biomarker Improvement After 90 Days Of Treatment
Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today provided
12-18 20:05
Gain Therapeutics Announces New Stock Offering Program
The latest announcement is out from Gain Therapeutics ( ($GANX) ). Gain Therape...
11-29 05:31
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025
Gain Therapeutics announced new preclinical data at Neuroscience 2025, showing GT-02287 reduces mitochondrial stress, improves neuronal survival, and enhances GCase trafficking to mitochondria, supporting its potential as a disease-modifying therapy for Parkinson’s disease. The findings are supported by three preclinical models: rat dopaminergic neurons, mouse PD models, and patient-derived fibroblasts with GBA1 mutation. GT-02287 decreased MIRO1...
11-20 12:00
Gain Therapeutics Q3 EPS $(0.15) Beats $(0.16) Estimate
Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.16) by 7.41 percent. This is a 11.76 percent increase over losses of $(0.17) per share from
11-12 20:14
Gain Therapeutics to Present at Neuroscience 2025
Gain Therapeutics announced a poster presentation at Neuroscience 2025 showcasing GT-02287, a small molecule allosteric modulator of glucocerebrosidase (GCase), targeting Parkinson's disease (PD) with or without GBA1 mutations. Preclinical data highlights disease-modifying effects, including restored enzymatic function, reduced pathology, and improved motor function in PD models. Phase 1 studies demonstrated favorable safety, tolerability, and ta...
10-30 11:00
Gain Therapeutics to Attend the 2025 Maxim Growth Summit
Gain Therapeutics, Inc. will participate in the 2025 Maxim Growth Summit on October 22-23 at The Hard Rock Hotel NYC. Gene Mack, President and CEO, will join a panel discussion on innovative approaches for neurogenerative diseases in clinical trials. Gain is a clinical-stage biotech company developing next-generation allosteric small molecule therapies for neurodegenerative diseases, rare genetic disorders, and oncology. Its lead candidate, GT-02...
10-16 11:00
